GlassScriptPhysician profile
Lance M Siegel
NPI 1184622672
$17,269.18
in general payments reported to CMS, 2019-2025
39 companies · $4,866 in 2025
The $4,866 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $1,548 · 2021: $1,662 · 2022: $2,552 · 2023: $2,333 · 2024: $2,894 · 2025: $4,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,093.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,107.01 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,439.64 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,761.07 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Qol Medical, LLC | $1,262.48 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $1,066.81 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $772.61 | 2022-2025 | |
| Pfizer INC. | $719.99 | 2019-2025 | |
| Celgene Corporation | $478.59 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $417.51 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $389.45 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $319.42 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $309.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $306.19 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $296.99 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $262.40 | 2020-2024 | Linzess |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $260.15 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $243.82 | 2019-2025 | |
| Vivus LLC | $215.61 | 2021-2025 | Qsymia, Pancreaze |
| Ferring Pharmaceuticals INC. | $201.00 | 2019-2025 | Rebyota |
| Redhill Biopharma INC. | $200.31 | 2020-2023 | Talicia |
| Lilly USA, LLC | $181.99 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $175.81 | 2020-2023 | Dificid |
| Braintree Laboratories, INC. | $148.29 | 2019-2023 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $100.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.74 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $68.31 | 2023 | |
| Endo Pharmaceuticals INC. | $65.39 | 2019-2020 | |
| Novo Nordisk INC | $50.51 | 2019-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $43.12 | 2022-2023 | Givlaari |
| Cumberland Pharmaceuticals, INC. | $28.44 | 2019-2023 | Kristalose |
| Alfasigma USA, INC. | $28.21 | 2020 | |
| Amgen INC. | $25.55 | 2023 | Amjevita |
| Covidien LP | $21.07 | 2019 | |
| Meridian Bioscience INC. | $20.32 | 2024 | |
| Evoke Pharma, INC. | $19.83 | 2021 | |
| Exact Sciences Corporation | $19.65 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $17.55 | 2019 | |
| Celltrion USA INC. | $14.01 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.